Can Fatty Liver Cause Gout? Causes and Links

Fatty liver and gout are two increasingly common conditions in the UK, and many people wonder whether one can cause the other. Fatty liver disease does not directly cause gout, but the two conditions are closely linked through shared metabolic mechanisms, including insulin resistance, obesity, and disordered uric acid handling. Understanding why they so often appear together, and what can be done to address both at once, is important for anyone managing either condition or trying to reduce their risk.

Can fatty liver cause gout, or do they just occur together?

Fatty liver does not directly cause gout, but both conditions share overlapping mechanisms, including insulin resistance and fructose metabolism, making co-occurrence common rather than coincidental.

Fatty liver disease does not directly cause gout, but the two conditions share overlapping biological mechanisms that make them very likely to occur together. Metabolic-associated steatotic liver disease (MASLD, previously called non-alcoholic fatty liver disease or NAFLD, and still referred to by that name in some UK materials) and gout are both strongly linked to insulin resistance, obesity, and disordered metabolism, which means a person who develops one condition is at meaningfully elevated risk of developing the other.

Gout arises when uric acid accumulates in the blood (a state called hyperuricaemia) and crystallises in joints, causing intense inflammation. The liver plays a central role in uric acid metabolism: it both produces uric acid through the breakdown of purines and influences how efficiently the kidneys excrete it. When the liver is affected by fat accumulation and low-grade inflammation, these processes can become dysregulated, contributing to raised uric acid levels.

Fructose metabolism is a particularly important link. Fructose, found in sugary drinks and ultra-processed foods, is metabolised predominantly in the liver and simultaneously promotes hepatic fat storage and drives uric acid production.^[8][9] A diet high in fructose can therefore worsen both conditions through a single shared pathway.

It is important to understand that the relationship is bidirectional rather than a simple cause-and-effect chain. Hyperuricaemia may promote hepatic inflammation and worsen liver fat accumulation, while liver disease can impair uric acid clearance. Clinicians and researchers increasingly view both conditions as expressions of the same underlying metabolic dysfunction, a perspective reflected in current European guidance on MASLD (EASL-EASD-EASO 2024 clinical practice guideline) and UK NICE guidance on NAFLD (NICE NG49).

Why do fatty liver and gout so often appear at the same time?

Fatty liver and gout co-occur because both are driven by metabolic syndrome, with insulin resistance being the key shared mechanism that simultaneously promotes hepatic fat deposition and reduces renal uric acid excretion.

Fatty liver and gout co-occur so frequently because they share a cluster of underlying risk factors collectively described as metabolic syndrome, which includes central obesity, high blood pressure, raised triglycerides, low HDL cholesterol, and impaired glucose regulation.^[4] Each of these factors independently raises the risk of both conditions, so when one is present, the others often are too.

Insulin resistance sits at the heart of this overlap. When cells respond poorly to insulin, the pancreas compensates by producing more of it. Elevated insulin levels reduce the kidneys' ability to excrete uric acid, partly by impairing urate transporter activity, causing uric acid to accumulate in the blood.^[10][11] At the same time, insulin resistance promotes fat deposition in the liver, setting the stage for MASLD. This single mechanism therefore drives both hyperuricaemia and hepatic steatosis simultaneously, as described in NICE CKS guidance on gout and in NICE NG49.

Chronic low-grade inflammation is another shared driver. Fat tissue, particularly visceral fat around the abdomen, releases pro-inflammatory cytokines that promote both hepatic inflammation and the joint inflammation characteristic of gout flares. Adipokine imbalance, including reduced adiponectin and raised leptin, further disrupts both uric acid handling and liver fat metabolism.

Genetic factors also contribute. Variants in genes such as SLC2A9 and ABCG2, which regulate uric acid transport, are associated with gout risk, while variants affecting lipid and glucose metabolism raise MASLD risk.^[13][14] Some individuals carry combinations of these variants, making them particularly susceptible to both conditions. Understanding this shared biology is clinically useful because it means that addressing the root metabolic causes, rather than treating each condition in isolation, is likely to produce the greatest long-term benefit.

What lifestyle changes can help both conditions at once?

Gradual weight loss of 5 to 10 per cent of body weight, reducing fructose and alcohol intake, and at least 150 minutes of weekly aerobic activity can meaningfully improve both fatty liver and gout.

Sustained, gradual weight loss is the single most effective lifestyle intervention for improving both fatty liver disease and gout simultaneously. NICE NG49 indicates that weight reduction of around 5 to 10 per cent of body weight can meaningfully reduce liver fat, and more substantial loss of 10 per cent or more is associated with improvement in liver inflammation and fibrosis.^[2][3] Weight loss is also associated with reductions in serum uric acid, which can reduce the frequency of gout flares. It is important that weight loss is gradual: rapid weight loss or prolonged fasting can temporarily raise uric acid levels and trigger gout flares, so a steady, sustainable approach is recommended. If you are starting urate-lowering therapy at the same time as making dietary changes, your GP may discuss short-term flare prophylaxis with you.

Dietary changes that benefit both conditions include:

• Reducing fructose and added sugar intake, particularly from sugary drinks, fruit juices, and ultra-processed foods, which drive both hepatic fat accumulation and uric acid production.

• Limiting alcohol, which raises uric acid levels and contributes directly to liver fat and inflammation.

• Reducing red meat and shellfish, which are high in purines and raise uric acid.

• Increasing vegetables, wholegrains, and low-fat dairy, which are associated with lower uric acid levels in observational studies, though these associations do not prove causality.

• Coffee consumption has been associated with lower uric acid levels and improved liver enzyme markers in observational research, though this should not be taken as a recommendation to increase intake beyond personal preference.

• Following a Mediterranean-style dietary pattern, which NICE and NHS guidance recognise as beneficial for metabolic health broadly.

Regular physical activity improves insulin sensitivity, reduces visceral fat, and supports both liver health and uric acid management. NHS guidance recommends at least 150 minutes of moderate-intensity aerobic activity per week, alongside muscle-strengthening activities on two or more days.^[5] Regular movement, including walking, contributes to the metabolic improvements that benefit both conditions, though the evidence specifically linking exercise to reduced gout flare frequency is limited and the primary benefit is through overall metabolic improvement.

For people exploring structured weight management support, Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of clinically appropriate options may be considered.

When should you see a GP about fatty liver and gout symptoms?

See your GP if you have recurrent gout flares, raised liver enzymes, or fatty changes on ultrasound, as both conditions require formal metabolic assessment and a coordinated management plan.

You should see your GP if you experience recurrent gout flares, persistent joint pain or swelling, or if you have been told you have raised liver enzymes or fatty changes on an ultrasound scan, as both conditions benefit from formal assessment and a coordinated management plan. Early review allows your GP to assess the full metabolic picture, including blood pressure, blood glucose, lipid levels, kidney function, and uric acid, rather than treating each symptom in isolation.

For gout, NICE CKS guidance recommends a treat-to-target approach: if urate-lowering therapy such as allopurinol is started, the aim is to reduce serum uric acid to below 300 micromoles per litre (or below 360 micromoles per litre in some cases), with the dose titrated gradually and flare prophylaxis considered during the early months of treatment. Your GP will advise on the appropriate target and monitoring schedule for your circumstances.

For fatty liver, NICE NG49 recommends that GPs use a fibrosis risk score such as the FIB-4 index or the NAFLD Fibrosis Score to assess whether further investigation or specialist referral is needed.^[2] In some cases, an enhanced liver fibrosis (ELF) blood test may be arranged. If fibrosis is suspected to be progressing, your GP may refer you to a hepatologist.

Specific symptoms that warrant a prompt GP appointment include:

• Frequent or increasingly severe gout attacks, particularly if affecting multiple joints or not settling within the expected timeframe with over-the-counter anti-inflammatories.

• Persistent fatigue, right-sided abdominal discomfort, or unexplained weight loss, which can occasionally indicate more advanced liver disease.

• Yellowing of the skin or eyes (jaundice), dark urine, or pale stools, which require urgent same-day assessment via your GP or NHS 111.

• Tophi (firm uric acid deposits under the skin), which suggest longstanding hyperuricaemia and indicate a need for urate-lowering therapy.^[6]

If you have an acutely hot, red, and swollen joint accompanied by fever or feeling generally unwell, seek urgent same-day assessment at your GP surgery or emergency department. Although this presentation can be a severe gout flare, it may also indicate septic arthritis, a joint infection that requires prompt diagnosis and treatment.

If you develop sudden, severe abdominal pain, particularly with vomiting, contact NHS 111 for urgent advice, as this may indicate acute pancreatitis, which can occasionally be associated with severe hypertriglyceridaemia in the context of metabolic syndrome.^[17] For any life-threatening emergency, such as collapse or severe chest pain, call 999 immediately.

Reporting any suspected adverse effects from prescribed medicines to the MHRA Yellow Card scheme helps improve safety monitoring for all patients.

Scientific References

1. EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
2. Metabolic dysfunction-associated steatotic liver disease (MASLD) — NICE guideline NG49.
3. Non-alcoholic fatty liver disease (NAFLD).
4. Metabolic syndrome.
5. Physical activity guidelines for adults aged 19 to 64.
6. Recommendations | Gout: diagnosis and management (NICE NG219).
7. Metabolic dysfunction-associated steatotic liver disease — recommendations for research (NG49).
8. Fructose and Cardiometabolic Health: What the Evidence From Sugar-Sweetened Beverages Tells Us.
9. Sugar consumption, metabolic disease and obesity: The state of the controversy.
10. Hyperuricemia and its related diseases: mechanisms and advances in therapy.
11. New insight into the management of renal excretion and hyperuricemia: Potential therapeutic strategies with natural bioactive compounds.
12. Research progress on the effects of sodium-glucose linked transporter 2 inhibitors on multiple metabolic disorders in metabolic syndrome.
13. Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study.
14. Genetic contributions to female gout and hyperuricaemia using genome-wide association study and polygenic risk score analyses.
15. Variants in urate transporters, ADH1B, GCKR and MEPE genes associate with transition from asymptomatic hyperuricaemia to gout: results of the first gout versus asymptomatic hyperuricaemia GWAS in Caucasians using data from the UK Biobank.
16. Metabolic dysfunction-associated steatotic liver disease: Evolution of the final terminology.
17. Impact of metabolic syndrome components on clinical outcomes in hypertriglyceridemia-induced acute pancreatitis.

Frequently Asked Questions